Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $5.0 million.

  • Conmed's Share-based Compensation fell 2064.18% to $5.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $28.3 million, marking a year-over-year increase of 1062.85%. This contributed to the annual value of $28.3 million for FY2025, which is 1063.67% up from last year.
  • As of Q4 2025, Conmed's Share-based Compensation stood at $5.0 million, which was down 2064.18% from $4.6 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Share-based Compensation peaked at $13.9 million during Q1 2025, and registered a low of $3.4 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $5.8 million (2022), whereas its average is $5.8 million.
  • Data for Conmed's Share-based Compensation shows a peak YoY increase of 12216.35% (in 2025) and a maximum YoY decrease of 2969.6% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Conmed's Share-based Compensation stood at $4.3 million in 2021, then soared by 32.89% to $5.8 million in 2022, then rose by 3.63% to $6.0 million in 2023, then increased by 4.99% to $6.3 million in 2024, then fell by 20.64% to $5.0 million in 2025.
  • Its Share-based Compensation stands at $5.0 million for Q4 2025, versus $4.6 million for Q3 2025 and $4.9 million for Q2 2025.